BillionToOne, Inc. (BLLN): Results of Operations and Financial Condition
BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991blln-earningspressrele.htm EX-99.1 Document BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to cr
How this was made
The 30-second read
Why it matters
Traders can update models using the reported Q2 revenue, margin, test volume, and free cash flow, then map the guidance range to expected delivery ramp around the scheduled commercial availability dates.
Market read
A company-specific earnings-and-guidance disclosure with concrete roadmap dates, giving traders a basis for near-term positioning and forward expectations.
What to watch
The guidance is reiterated rather than raised, so upside may be capped unless traders view the Aug 17 Unity expansion and Sep 1 Northstar Origin as near-term demand inflection points.
Background
This SEC 8-K (Item 2.02) reports BillionToOne’s Q2 2026 results and reiterates full-year 2026 revenue guidance, alongside product roadmap updates.
Ticker impact
BillionToOne reported Q2 2026 revenue of $109.4M, reiterated 2026 revenue guidance of $450M to $465M, and detailed upcoming product launches.
Likely positive bias for the next session as traders price in stronger Q2 growth, higher gross margin, and the Aug 17 and Sep 1 launch milestones.
The filing includes specific, time-relevant datapoints: Q2 revenue up 64% YoY, gross margin 70%, operating income turning positive, free cash flow of $5.1M, and a reiterated full-year revenue range.
Market effects
Strength in cfDNA and oncology molecular diagnostics execution may reinforce investor appetite for profitable growth in next-gen diagnostics.
Limited direct regional spillover; primarily affects US-listed biotech/diagnostics sentiment.
Modest global relevance, as the disclosure is company-specific and guidance-focused.
Counterpoint
Despite strong growth, operating expenses rose 59% YoY, so the sustainability of profitability could be questioned if investment intensity continues.
Key entities
- public_companyBillionToOne, Inc.
NASDAQ-listed molecular diagnostics company reporting Q2 2026 results and reiterating 2026 revenue guidance.
- productUnity Fetal Risk Screen
Expanded 130-gene panel planned for commercial availability on Aug 17, 2026.
- productNorthstar Origin
Add-on tissue-of-origin feature planned for commercial availability on Sep 1, 2026.
- productNorthstar Response
Referenced in peer-reviewed data published in The Journal of Liquid Biopsy with Allegheny Health Network.
